Compare MONDELEZ INTERNATIONAL INC Common Stock (MDLZ) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MONDELEZ INTERNATIONAL INC Common Stock vs Neurocrine Biosciences Inc — how do they compare? MONDELEZ INTERNATIONAL INC Common Stock trades at $59.85 (market cap $77.37B), while Neurocrine Biosciences Inc trades at $179 (market cap $17.40B). The key difference: MONDELEZ INTERNATIONAL INC Common Stock is far larger — about 4.4× Neurocrine Biosciences Inc's market cap, and MONDELEZ INTERNATIONAL INC Common Stock pays a 3.32% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| MDLZ | NBIX | |
|---|---|---|
Market Cap | $77.37B | $17.40B |
Sector | Consumer Staples | Health |
52-Week High | $70.75 | $180.55 |
52-Week Low | $51.51 | $123.10 |
Enterprise Value | $97.46B | $16.49B |
Dividend Yield | 3.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mondelez International (MDLZ) trades at $59.86, down 1.87% today but maintains a bullish technical signal with strong moving average support. The company reported Q1 2026 EPS of $0.67, beating expectations, and shows consistent revenue growth reaching $38.54B in 2025. Analyst consensus is strongly bullish with a $68.00 price target, representing 13.6% upside potential from current levels.
MDLZ offers stable dividend income and brand strength but faces margin compression risks from input cost inflation. The upcoming Q2 2026 earnings report on July 28, 2026 serves as the next major catalyst. While valuation multiples appear elevated, the company's market leadership and innovation pipeline support long-term growth prospects despite near-term profitability challenges.
Neurocrine Biosciences (NBIX) trades at $173.00, up 1.24% today, with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with Q1 2026 EPS of $1.94 beating expectations by 59%, revenue growth to $3.1B in 2026, and net income margin expanding to 21.55%. Recent news highlights executive appointments and positive clinical trial updates for crinecerfont, supporting growth prospects.
Outlook remains positive with 86% analyst buy ratings and a $196.08 consensus price target implying 13% upside. Key risks include execution of pipeline developments and integration of acquisitions. The stock's valuation at P/E 26.62 appears reasonable given earnings growth trajectory and strong profitability metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MONDELEZ INTERNATIONAL INC Common Stock
Mondelez has operated as an independent organization since its split from the former Kraft Foods North American grocery business in October 2012. The firm is a leading player in the global snack arena with a presence in the biscuit (47% of sales), chocolate (32%), gum/candy (10%), beverage (4%), and cheese and grocery (7%) aisles. Mondelez's portfolio includes well-known brands like Oreo, Chips Ahoy, Halls, Trident, and Cadbury, among others. The firm derives around one third of revenue from developing markets, nearly 40% from Europe, and the remainder from North America.
Read more on MDLZ →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
